Eye - retinal vein occlusion

The PBS subsidises aflibercept and ranibizumab for patients with branched retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) with macular oedema.

Patient eligibility

Treatment with aflibercept and ranibizumab can be subsidised through the Pharmaceutical Benefits Branch (PBS) under the National Health Act 1953, Section 85 for patients with retinal vein occlusion with macular oedema.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing aflibercept and ranibizumab.

Applications

Patients must be treated by an ophthalmologist or in consultation with an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Initial treatment

Make all initial applications for authority approval to prescribe aflibercept and ranibizumab for the treatment of patients with retinal vein occlusion with macular oedema in writing and:

All applications must include the completed:

If urgent, you can fax the first authority application to us on 1300 093 177 Monday to Friday during operating hours from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.

Continuing treatment

To make continuing applications for treatment with aflibercept and ranibizumab call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 April 2018